ๆญฃๅœจๅŠ ่ฝฝ่ง†้ข‘...

่ง†้ข‘ๅŠ ่ฝฝๅคฑ่ดฅ

่ฟ”ๅ›ž้ฆ–้กต

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Renowned scientist and entrepreneur Greg Verdine announced $263M in new funding for his company LifeMine Therapeutics. Participating investors include names like Bezos and Gates. See the full interview:

BiotechTV's profile picture

BiotechTV

11,846 subscribers

20,050 ๆฌก่ง‚็œ‹ โ€ข 12 ๅคฉๅ‰ โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

0 ๆก่ฏ„่ฎบ

ๆš‚ๆ— ่ฏ„่ฎบ

ๅŽŸๅง‹ๅธ–ๅญ็š„่ฏ„่ฎบๅฐ†ๆ˜พ็คบๅœจ่ฟ™้‡Œ

็›ธๅ…ณ่ง†้ข‘

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:
3:36

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:

BiotechTV

20,894 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:
3:01

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV

22,305 ๆฌก่ง‚็œ‹ โ€ข 1 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:
7:20

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:

BiotechTV

37,174 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:
5:19

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:
4:17

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:

BiotechTV

18,780 ๆฌก่ง‚็œ‹ โ€ข 9 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:
4:58

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:

BiotechTV

24,695 ๆฌก่ง‚็œ‹ โ€ข 6 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:
7:29

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:

BiotechTV

42,139 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:
4:35

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:

BiotechTV

19,198 ๆฌก่ง‚็œ‹ โ€ข 10 ไธชๆœˆๅ‰

๐“๐ก๐ž ๐’๐ญ๐ฎ๐๐ข๐จ ๐š๐ญ ๐Š๐ž๐ง๐๐š๐ฅ๐ฅ ๐’๐ช๐ฎ๐š๐ซ๐ž: Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP. Full video:
7:30

๐“๐ก๐ž ๐’๐ญ๐ฎ๐๐ข๐จ ๐š๐ญ ๐Š๐ž๐ง๐๐š๐ฅ๐ฅ ๐’๐ช๐ฎ๐š๐ซ๐ž: Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP. Full video:

BiotechTV

11,800 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy. See the whole interview here:
1:05

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy. See the whole interview here:

BiotechTV

16,344 ๆฌก่ง‚็œ‹ โ€ข 7 ไธชๆœˆๅ‰

๐€๐ˆ ๐๐ž๐ฐ๐ฌ: Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today. Full video:
3:11

๐€๐ˆ ๐๐ž๐ฐ๐ฌ: Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today. Full video:

BiotechTV

15,086 ๆฌก่ง‚็œ‹ โ€ข 8 ไธชๆœˆๅ‰

Skild AI is now worth $14B!! - about 3 times the $4.5B valuation from the last funding round reported to have closed six months ago The company has just announced raising $1.4B in Series C funding at a $14B valuation led by SoftBank, with participation from NVIDIA, Macquarie Capital, and Jeff Bezos. Other notable investors include LG, Samsung, and Salesforce Ventures. In 2025, the company grew from zero to approximately $30M in revenue in just a few months. Skild is building an omni-bodied brain to control any robot for any task.
0:34

Skild AI is now worth $14B!! - about 3 times the $4.5B valuation from the last funding round reported to have closed six months ago The company has just announced raising $1.4B in Series C funding at a $14B valuation led by SoftBank, with participation from NVIDIA, Macquarie Capital, and Jeff Bezos. Other notable investors include LG, Samsung, and Salesforce Ventures. In 2025, the company grew from zero to approximately $30M in revenue in just a few months. Skild is building an omni-bodied brain to control any robot for any task.

The Humanoid Hub

12,980 ๆฌก่ง‚็œ‹ โ€ข 7 ไธชๆœˆๅ‰

Big deals and small molecules with Nimbus Therapeutics CEO Jeb Keiper. Full video:
2:24

Big deals and small molecules with Nimbus Therapeutics CEO Jeb Keiper. Full video:

BiotechTV

29,583 ๆฌก่ง‚็œ‹ โ€ข 3 ๅนดๅ‰

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:
3:49

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:

BiotechTV

25,829 ๆฌก่ง‚็œ‹ โ€ข 7 ไธชๆœˆๅ‰

In June, Melinda French Gates announced $215 million in additional funding to focus on womenโ€™s reproductive and midlife health. TIME asked her why she chooses to invest in womenโ€™s health and why she thinks it's critical at this time in particular. Read the full interview with Gates here:
1:00

In June, Melinda French Gates announced $215 million in additional funding to focus on womenโ€™s reproductive and midlife health. TIME asked her why she chooses to invest in womenโ€™s health and why she thinks it's critical at this time in particular. Read the full interview with Gates here:

TIME

25,549 ๆฌก่ง‚็œ‹ โ€ข 2 ไธชๆœˆๅ‰

๐…๐ซ๐จ๐ฆ ๐’๐ž๐จ๐ฎ๐ฅ: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:
4:12

๐…๐ซ๐จ๐ฆ ๐’๐ž๐จ๐ฎ๐ฅ: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:

BiotechTV

15,588 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!
0:48

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!

BiotechTV

20,583 ๆฌก่ง‚็œ‹ โ€ข 1 ไธชๆœˆๅ‰